Progressing first-in-class, tissue-tethered autoimmune platform – Type 1 diabetes candidate on track for CTA submission in 2025; first universal candidate targeting CD1a initially for atopic ...

COVAX-19 is under clinical development by Vaxine and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Is NVAX stock a sell in December 2024? Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

As US Surgeon General Dr. Vivek Murthy nears the end of his second term as the nation’s doctor, a final diagnosis of his ...

A universal flu vaccine would be a game changer. Could artificial intelligence help us defeat influenza once and for all?

The science has proven that gene therapies are effective treatments, and they have given hope to patients and their families ...

He emphasized that in its current form, HMPV is unlikely to cause severe infections, even amid global concerns of a coronavirus-like outbreak.

Weight loss is a complex process as there are several angles that need to be addressed Some supplement providers emphasize the importance of strengthening liver function for healthy metabolism while o ...

The already crowded field of biomarker-targeted drugs is poised to only get busier with new biomarkers, ADCs, and cancer vaccines.